Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

When I did some homework* months ago to better understand tumors and efficacy, I remember an article that talked about tumors not being characterized by 1 single cell type, but instead made of several diverse mis-functioning cell types. One of the criticisms of using single cell line tumor for in vitro testing (like the ones CTIX uses for lung cancer, breast cancer etc.) is that these are homogenous tumors which won’t exist in the real world (in patients). If K activates p53, it will never destroy entire tumors unless the tumor is primarily comprised of dysfunctional p53, which may be common, but certainly not always the case. That, I think, is why you get Menon saying the clinical trial is progressing on par with the preclinical trials, because it is. It’s just that real world tumors are not homogenous, so in many instances, it will not and cannot completely eliminate the tumor, yet is still having a significant impact, leading to stabilization.

*Disclaimer – this is from a layman.